News

Feb 20, 2024 | BALTIMORE – Complete Omics Inc., a leader in clinical proteomics and multi-omics molecular diagnostics, proudly announces its recent achievement of the California Clinical Laboratory License. This milestone marks a pivotal expansion in the company’s ability to serve patients and healthcare providers across California, the most populous state in the U.S.

With this new licensure, Complete Omics is now authorized to collect clinical samples directly from California, unlocking access to its state-of-the-art proteomics-based diagnostic solutions for a population of over 48 million. As one of the most rigorous regulatory approvals in the country, the California Clinical Laboratory License further solidifies Complete Omics’ position as a premier provider of high-quality, reliable, and innovative diagnostic services.

This achievement follows Complete Omics’ prior CLIA and CAP certifications, which affirm the laboratory’s adherence to the highest standards in diagnostic accuracy, compliance, and patient safety. Additionally, the company’s enrollment in the Medicare system has already expanded access to its cutting-edge diagnostic solutions for a broader patient population.

“Receiving the California Clinical Laboratory License is a transformative moment for Complete Omics,” said Qing Wang, Founder and CEO of Complete Omics Inc. “With this authorization, we can now directly serve millions of patients and healthcare providers in California, expanding access to our breakthrough proteomics-based diagnostics and accelerating early disease detection and personalized treatment. Given California’s vast population and its position as a global healthcare hub, this will significantly increase our clinical diagnostic revenue in the coming year.”

As Complete Omics continues to lead in ultra-deep protein detection and high-throughput multi-omics cohort analysis, the company remains committed to delivering accessible, best-in-class clinical diagnostics and research services. The California Clinical Laboratory License further reinforces its mission to set new benchmarks in diagnostic precision and accessibility, helping more patients benefit from next-generation proteomics-driven healthcare solutions.

For more information on Complete Omics and its clinical diagnostic services, please visit [Company Website].

About Complete Omics Inc.
Complete Omics Inc. is a biotechnology company pioneering clinical proteomics and multi-omics molecular diagnostics to revolutionize early disease detection and personalized treatment. With CLIA and CAP certifications, Medicare enrollment, and now the California Clinical Laboratory License, Complete Omics is at the forefront of advancing precision diagnostics and transforming patient care worldwide.